ACTRN12620000016932尚未招募未知
A single-centre, parallel-arm trial evaluating the effects of arthroscopic Bankart repair and open Latarjet shoulder stabilisation procedures on shoulder joint neuromechanics and function
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •1. Currently or recently (past 12 months) engaged in an overhead contact sport (i.e. Australian Rules Football, American Football, Rugby League or Union, Lacrosse)
- •2. Experienced one or more traumatic shoulder instability injury (i.e. subluxation or dislocation) resulting in a surgical stabilisation procedure being required (experimental groups only)
- •3. Willing, able and mentally competent to provide informed consent.
排除标准
- •1. Prior history of shoulder instability injury or reported perceived symptoms of shoulder instability as deemed by the Oxford Instability Score questionnaire.
- •2. Prior history of upper limb reconstructive surgery.
- •3. Known neurological condition affecting the upper limb.
- •4. Presence of adhesive capsulitis of the shoulder.
- •5. Presence of a larger rotator cuff tear as determined via magnetic resonance imaging.
- •6. Contraindications for undergoing magnetic resonance imaging (e.g. metallic foreign bodies, heart pacemakers).
- •7. Foreseeable circumstances that will result in the participant being unavailable for the 12-month follow-up period.
研究者
相似试验
已完成
不适用
A multi-centre clinical trial evaluating the safety and functionality of a medical imaging device for tissue review during breast-conserving surgery.Cancer - BreastBreast CancerACTRN12623000205639OncoRes Medical Pty Ltd30
招募中
1 期
Desensitisation with imlifidase prior to kidney transplant in highly sensitised childreHighly sensitised paediatric patients with a positive crossmatch against a living or deceased donor kidney.MedDRA version: 20.0Level: PTClassification code: 10023439Term: Kidney transplant rejection Class: 100000004870CTIS2022-500230-28-00Hansa Biopharma AB8
进行中（未招募）
不适用
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)EUCTR2008-004007-64-DEGlaxoSmithKline Biologicals115
进行中（未招募）
1 期
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanomaEUCTR2008-004007-64-FIGlaxoSmithKline Biologicals125
进行中（未招募）
不适用
A study to test the benefit of a new anti-cancer Treatment in patients with unresectable advanced melanomaFirst-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanomaMedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-004007-64-ITGlaxoSmithKline Biologicals115